Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3903 ARTÍCULOS , VIENDO DEL 2656 AL 2670

Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction

Ross CA, Pantelyat A, Kogan J, Brandt J.

Mov Disord. 2014 Sep 15;29(11):1351-8. doi: 10.1002/mds.26012.

Animal models of Huntington's disease for translation to the clinic: best practices

Menalled L, Brunner D.

Mov Disord. 2014 Sep 15;29(11):1375-90. doi: 10.1002/mds.26006.

Preclinical models: needed in translation? A Pro/Con debate

Philips T, Rothstein JD, Pouladi MA.

Mov Disord. 2014 Sep 15;29(11):1391-6. doi: 10.1002/mds.26010.

Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches

Sampaio C, Borowsky B, Reilmann R.

Mov Disord. 2014 Sep 15;29(11):1419-28. doi: 10.1002/mds.26021.

Stem cells for cell replacement therapy: a therapeutic strategy for HD?

Rosser A, Svendsen CN.

Mov Disord. 2014 Sep 15;29(11):1446-54. doi: 10.1002/mds.26026.

Disruption of striatal-enriched protein tyrosine phosphatase (STEP) function in neuropsychiatric disorders

Karasawa T, Lombroso PJ.

Neurosci Res. 2014 Dec;89:1-9. doi: 10.1016/j.neures.2014.08.018. Epub 2014 Sep 10.

Neurodegenerative disorders: dysregulation of a carefully maintained balance?

Swart C, Haylett W, Kinnear C, Johnson G, Bardien S, Loos B.

Exp Gerontol. 2014 Oct;58:279-91. doi: 10.1016/j.exger.2014.09.003. Epub 2014 Sep 9.

BDNF signaling and survival of striatal neurons

Baydyuk M, Xu B.

Front Cell Neurosci. 2014 Aug 28;8:254. doi: 10.3389/fncel.2014.00254. eCollection 2014.

Cholesterol in brain disease: sometimes determinant and frequently implicated

Martín MG, Pfrieger F, Dotti CG.

EMBO Rep. 2014 Oct;15(10):1036-52. doi: 10.15252/embr.201439225. Epub 2014 Sep 15.

P2X7 receptor: an emerging target in central nervous system diseases

Sperlágh B, Illes P.

Trends Pharmacol Sci. 2014 Oct;35(10):537-47. doi: 10.1016/j.tips.2014.08.002. Epub 2014 Sep 12.

Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System

Janssens J, Etienne H, Idriss S, Azmi A, Martin B, Maudsley S.

Front Endocrinol (Lausanne). 2014 Sep 1;5:142. doi: 10.3389/fendo.2014.00142. eCollection 2014.

Cholinergic system dysfunction and neurodegenerative diseases: cause or effect?

Tata AM, Velluto L, D'Angelo C, Reale M.

CNS Neurol Disord Drug Targets. 2014;13(7):1294-303. doi: 10.2174/1871527313666140917121132.

Regulatory cascade of neuronal loss and glucose metabolism

Hassan M, Sehgal SA, Rashid S.

CNS Neurol Disord Drug Targets. 2014;13(7):1232-45. doi: 10.2174/1871527313666140917120444.

Omental transplantation for neurodegenerative diseases

Rafael H.

Am J Neurodegener Dis. 2014 Sep 6;3(2):50-63. eCollection 2014.

Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea

Brogna C, Mariotti P, Manna R.

Lupus. 2014 Dec;23(14):1449-51. doi: 10.1177/0961203314551084. Epub 2014 Sep 18.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias